June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Novel Light Intensity Device (LuxIQ) for Quantitative Evaluation of Dry Eye Syndrome
Author Affiliations & Notes
  • Harvey Fishman MD PHD
    FishmanVision , Palo Alto, California, United States
  • Peter Borden
    Jasper Ridge, Inc., San Mateo, California, United States
  • Michele Klein
    Jasper Ridge, Inc., San Mateo, California, United States
  • Footnotes
    Commercial Relationships   Harvey Fishman MD PHD, FishmanVision (P); Peter Borden, Jasper Ridge, Inc. (P), Jasper Ridge, Inc. (E); Michele Klein, Jasper Ridge, Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2705. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Harvey Fishman MD PHD, Peter Borden, Michele Klein; Novel Light Intensity Device (LuxIQ) for Quantitative Evaluation of Dry Eye Syndrome. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2705.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effectiveness of a novel device (LuxIQ) that quantifies light sensitivity in patients reporting Dry Eye Syndrome (DES) symptoms, and whether light sensitivity measurement is an effective indicator of DES.

Methods : 15 patients reporting DES symptoms were recruited during their regularly scheduled visit to a Dry Eye clinic. A routine screening exam was conducted, including Non-Invasive Tear Break-up Time (NIBUT), Schirmer strips, and Osmolarity. In addition, each patient was asked to adjust a device (LuxIQ™, Jasper Ridge Inc) to their preferred illuminance and white light color temperature on a 40-cm near vision chart (Colenbrander Mixed Contrast), over an illuminance range of 0-5000 lux and color temperature range of 2,700 to 6,500°K. Measurement was bilateral (both eyes open) Patients were not told the purpose of this measurement. 8 control subjects, who did not report DES symptoms, were also measured for illuminance and color temperature preference.

Results : The average illuminance and color temperature for the DES patients was 1750±753 lux and 4507±784°K, and for the controls 2643±1435 lux and 5000±852°K (see figure 1). The DES distribution shows a strong peak between 1000 and 2000 lux, and is significantly lower than the control (p=.21). The NIBUT, Schirmer and Osmolarity scores showed no correlation to one another. Interestingly, the sole correlation between methods seen is between illuminance and NIBUT for patients with illuminance <3000 lux and the time in both eyes <5 seconds, with a linear r2 correlation of 0.91.

Conclusions : We observed strong evidence of a measurable relation between preferred illuminance and DES symptoms. Of the four diagnostic methods used in this study, preferred illuminance was the most consistent, a promising result as it is also the quickest, simplest, and least invasive of the methods. The correlation between short NIBUT times and preferred illuminance further supports the conclusion that preferred illuminance is a valid indicator of DES. We are continuing this IRB-approved study, and expect to evaluate significantly more patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×